Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/19 cls
bluebird bio Inc. (NASDAQ:BLUE) JPMorgan Cory Kasimov New Overweight 11% $33.99
Wedbush David Nierengarten New Outperform
Kasimov set a $44 target. He believes bluebird's

Read the full 580 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE